Acta Pharmaceutica Sinica B impact factor, indexing, ranking (2024)


acta

Aim and Scope

The Acta Pharmaceutica Sinica B is a research journal that publishes research related to Pharmacology, Toxicology and Pharmaceutics. This journal is published by the Elsevier BV. The ISSN of this journal is 22113843, 22113835. Based on the Scopus data, the SCImago Journal Rank (SJR) of acta pharmaceutica sinica b is 2.518.

Also, please check the following important details about acta pharmaceutica sinica b: Publisher, ISSN, Ranking, Indexing, Impact Factor (if applicable), Publication fee (APC), Review Time, and Acceptance Rate.

According to Clarivate's JCR, journals indexed in SCIE/SSCI have an impact factor.

Acta Pharmaceutica Sinica B Ranking

Impact Factor: 14.7
5-Year JIF: 14.1
SJR (SCImago Journal Rank): 2.518
Quartile: Q1

The latest Impact Factor list (JCR) is released in June 2024.

The Impact Factor of Acta Pharmaceutica Sinica B is 14.7.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times its articles are cited.

The impact factor was devised by Eugene Garfield, the founder of the Institute for Scientific Information (ISI) in Philadelphia. Impact factors began to be calculated yearly starting from 1975 for journals listed in the Journal Citation Reports (JCR). ISI was acquired by Thomson Scientific & Healthcare in 1992, and became known as Thomson ISI. In 2018, Thomson-Reuters spun off and sold ISI to Onex Corporation and Baring Private Equity Asia. They founded a new corporation, Clarivate, which is now the publisher of the JCR.


Important Metrics

Journal Title: Acta Pharmaceutica Sinica B
Publisher: Elsevier BV
ISSN: 22113843, 22113835
Type: journal
Journal Scope: Pharmacology, Toxicology and Pharmaceutics
Country: Netherlands
H-Index: 79
SJR: 2.518
Quartile: Pharmacology, Toxicology and Pharmaceutics (miscellaneous) (Q1)

Indexing

The acta pharmaceutica sinica b is indexed in:

An indexed journal means that the journal has gone through and passed a review process of certain requirements done by a journal indexer.

The Web of Science Core Collection includes the Science Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI), Arts & Humanities Citation Index (AHCI), and Emerging Sources Citation Index (ESCI).


Acta Pharmaceutica Sinica B Impact Factor 2024

The latest impact factor of acta pharmaceutica sinica b is 14.7 which is recently updated in June, 2024.

The impact factor (IF) is a measure of the frequency with which the average article in a journal has been cited in a particular year. It is used to measure the importance or rank of a journal by calculating the times it's articles are cited.

Note: Every year, The Clarivate releases the Journal Citation Report (JCR). The JCR provides information about academic journals including impact factor. The latest JCR was released in June, 2023. The JCR 2024 will be released in the June 2024.


Quartile

The latest Quartile of acta pharmaceutica sinica b is Q1.

Each subject category of journals is divided into four quartiles: Q1, Q2, Q3, Q4. Q1 is occupied by the top 25% of journals in the list; Q2 is occupied by journals in the 25 to 50% group; Q3 is occupied by journals in the 50 to 75% group and Q4 is occupied by journals in the 75 to 100% group.


Publication fee

Based on the Official Journal Homepage, the acta pharmaceutica sinica b does not charge any publication fee.

An article processing charge (APC), also known as a publication fee, is a fee which is sometimes charged to authors. Most commonly, it is involved in making a work available as open access (OA), in either a full OA journal or in a hybrid journal.


Journal Publication Time

The Journal Publication Time means the average number of weeks between article submission and publication. According to the journal website, the acta pharmaceutica sinica b publishes research articles in 19 weeks on an average.



Call for Papers

Visit to the official website of the journal/ conference to check the details about call for papers.

How to publish in Acta Pharmaceutica Sinica B?

If your research is related to Pharmacology, Toxicology and Pharmaceutics, then visit the official website of acta pharmaceutica sinica b and send your manuscript.

Tips for publishing in Acta Pharmaceutica Sinica B:

Acceptance Rate

Acceptance rate is the ratio of the number of articles submitted to the number of articles published. Researchers can check the acceptance rate on the journal website. Alternatively, they can contact the editor of the journal.

Final Summary

  • The impact factor of acta pharmaceutica sinica b is 14.7.
  • The acta pharmaceutica sinica b is a reputed research journal.
  • It is published by Elsevier BV.
  • The journal is indexed in UGC CARE, Scopus, SCIE, DOAJ.
  • It is an open access journal.
  • The (SJR) SCImago Journal Rank is 2.518.
  • The publication time (Average number of weeks between article submission and publication) of the journal is 19 weeks.
  • Based on the Official Journal Homepage, the acta pharmaceutica sinica b does not charge any publication fee.

Sources: http://www.journals.elsevier.com/acta-pharmaceutica-sinica-b







SIMILIAR JOURNALS


ALCOHOL

ISSN: 0741-8329
Publisher: ELSEVIER SCIENCE INC

ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY

ISSN: 0362-1642
Publisher: ANNUAL REVIEWS

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

ISSN: 1742-7835
Publisher: WILEY

BMC PHARMACOLOGY & TOXICOLOGY

ISSN:
Publisher: BMC

CHEMICO-BIOLOGICAL INTERACTIONS

ISSN: 0009-2797
Publisher: ELSEVIER IRELAND LTD

DRUG AND CHEMICAL TOXICOLOGY

ISSN: 0148-0545
Publisher: TAYLOR & FRANCIS LTD

DRUGS

ISSN: 0012-6667
Publisher: ADIS INT LTD

DRUG SAFETY

ISSN: 0114-5916
Publisher: ADIS INT LTD

ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY

ISSN: 1382-6689
Publisher: ELSEVIER

EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY

ISSN: 1742-5255
Publisher: TAYLOR & FRANCIS LTD

TOP RESEARCH JOURNALS

Credit and Source: Scopus, Clarivate, UGC CARE.